Arizona is currently home to 1684 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
NCT04628767
Recruiting
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Kingman Regional Medical Center, Kingman, Arizona
Conditions: Renal Pelvis and Ureter Urothelial Carcinoma
Register for Updates
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Local Institution - 007-556-A, Goodyear, Arizona
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
National Cancer Institute "Cancer Moonshot Biobank"
NCT04314401
Recruiting
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
07/11/2025
Locations: Kingman Regional Medical Center, Kingman, Arizona
Conditions: Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Acute Myeloid Leukemia, Metastatic Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Multiple Myeloma, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Fallopian Tube Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Melanoma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Triple-Negative Breast Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
Register for Updates
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251
Recruiting
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/11/2025
Locations: Retinal Research Institute, LLC, Phoenix, Arizona
Conditions: Neovascular Age-Related Macular Degeneration
Register for Updates
Longitudinal Early-onset Alzheimer's Disease Study Protocol
NCT03507257
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
ALL
Ages:
Between 40 years and 64 years
Trial Updated:
07/11/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Register for Updates
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/10/2025
Locations: Investigative Site US020, Phoenix, Arizona
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065
Recruiting
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2025
Locations: Adobe Clinical Research, LLC, Tucson, Arizona
Conditions: MASH
Register for Updates
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Chandler Clinical Trials, Chandler, Arizona
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320
Recruiting
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2025
Locations: Ima Clinical Research Phoenix (Alea) /ID# 275737, Phoenix, Arizona
Conditions: Generalized Anxiety Disorder (GAD)
Register for Updates
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
NCT06806657
Recruiting
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/10/2025
Locations: Research Solutions of Arizona, Litchfield Park, Arizona
Conditions: Hereditary Angioedema
Register for Updates
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247
Recruiting
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: A40, Tucson, Arizona
Conditions: Myasthaenia Gravis
Register for Updates
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert, Arizona
Conditions: Sjögren's Syndrome
Register for Updates